NewGam
Phase 3Biologic
OctapharmaNewGam is one of 98 biologic programs targeting Immunodeficiency Disease. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
135 competitors in Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Nplate
AmgenPhase 3
Rysodeg
UCBPhase 3
Cellcept
RochePhase 3
Doptelet
AAkarx
Phase 3
Vyvgart
ArgenxPhase 3
Fabhalta
Johnson & JohnsonPhase 3
Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Avlosulfon
AAlmirall, S.A.
Phase 3
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immune Thrombocytopenia1 trial
Immunodeficiency Disease1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NewGam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company